IL33
IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Overview
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signalling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 1 · What it is
IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 2 · What goes wrong in cancer
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signalling pathways in target cells.
- 3 · How drugs use it
No product in this corpus aims at IL33 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:16028 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95760 (protein name, function text, keywords and locations (REST API)); CIViC gene IL33 (1 evidence items, 0 assertions, 1 variants; diseases: High Grade Glioma (GraphQL API, CC0))
Biology
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signalling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as an enhancer of polarisation of alternatively activated macrophages. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury. Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages. Location: Nucleus; Chromosome; Cytoplasm; Cytoplasmic vesicle, secretory vesicle (UniProt). Locus 9p24.1 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: High Grade Glioma.
Latest papers
topQuery for this target: (TITLE:"IL33" OR ABSTRACT:"IL33" OR TITLE:"interleukin 33" OR ABSTRACT:"interleukin 33" OR TITLE:"Interleukin-33" OR ABSTRACT:"Interleukin-33" OR TITLE:"DVS27" OR ABSTRACT:"DVS27" OR TITLE:"DKFZp586H0523" OR ABSTRACT:"DKFZp586H0523" OR TITLE:"NF-HEV" OR ABSTRACT:"NF-HEV") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL33, not a curated reading list.